Meet Inspiring Speakers and Experts at our 3000+ Global Conference Series Events with over 1000+ Conferences, 1000+ Symposiums
and 1000+ Workshops on Medical, Pharma, Engineering, Science, Technology and Business.

Explore and learn more about Conference Series : World’s leading Event Organizer


Christina YK Leung

Christina YK Leung

Title: Drugs use in Biliary atresia and the roles of clinical pharmacist


Biography: Christina YK Leung


Biliary atresia (BA) is a condition in which infl ammation develops within the bile ducts around the time of birth. This leads to bile duct damage and reduces the fl ow of the bile which subsequently causes scarring of the liver. The initial treatment for biliary atresia is a surgical operation called the “Kasai Porteoenterostomy” (KPE). The aim of KPE is to make a drainage channel to allow bile to drain from the liver. Before the surgery, the patient will be prescribed with fat-soluble vitamins for patients with prolonged jaundice. Examples are multivitamin preparations (Abidec® or Dalivit® drops in the UK), vitamin K preparations (phytomenadione injection which can be given by oral, IV or IM routes and menadiol tablet), Vitamin E (tocopheryl acetate), and Vitamin D (Alfacalcidol). 24 to 48 hours before the surgery, the patients will receive bowel preparations and the common ones are Lactulose liquid, Neomycin liquid, and Metronidazole suspension. Aft er the operation, the patient will receive drugs via intravenous or intramuscular route for about 3 to 5 days, standard maintenance IV fl uid will be given for about 3 to 4 days. Nurse Controlled Analgesia (NCA) IV pump with morphine is always used for the initial 3 days, and the patient is also prescribed with regular paracetamol (IV or rectal) for breakthrough pain for about 3 days then change to oral. Prophylactic IV antibiotics will be given aft er the surgery for at least 72 hours. Examples are Gentamicin and Piperacillin/Tazobactam as dual therapies. Aft er 72 hours, if no high temperature is developed and the oral feeds are started, the prophylactic antibiotics can be changed to oral for 28 days (an example is oral Cefalexin). Ranitidine is also used to prevent a stress-induced ulcer. Intramuscular vitamins are used post-surgery. Examples are Vitamin D 30,000 units (60,000 units if radiological rickets is present), Vitamin E 10mg per kg, Vitamin A 10,000 units are given at the discretion of hepatologist (usually for patients with late diagnosis). Aft er day 5 of operations, the patient may start oral therapies. Additional oral vitamins
are necessary post-surgery for about 6 months. Examples are Vitamin K, Vitamin E, and multivitamin drops. Oral Phenobarbitone (alcoholfree liquid or tablet) helps to increase bile fl ow and hence to reduce itching symptom. Th e recommended dose is 15mg daily, increasing to 45mg daily in steps of 15mg per week. Colestyramine helps to remove the bile salts which cause jaundice and itchiness. Since Colestyramine can reduce the absorption of some drugs, especially vitamins, it is recommended to leave vitamin preparations at least 2 hours before or 4 hours after giving Colestyramine. Spironolactone suspension helps the patient reduces the amount of fl uid accumulated as a result of ascites, but it is not needed in all cases. Th ere have been clinical studies to use high dose oral steroids (oral prednisolone) post KPE to benefi t in reduction of postoperative bilirubin and clearance of jaundice. However, the fi ndings show that the eff ect of steroids may be limited or inhibited by an increasing degree of fi brosis and onset of cirrhosis. If KPE is successful, many of these medicines can be stopped over time. If KPE fails, the liver transplant can be one of the treatment options. Th e care of the biliary atresia patients is best with the multi-disciplinary approach, and clinical pharmacists play a signifi cant role in this care management. Examples of the contributions are dosage recommendations, choice of drugs, stopping or initiation of a therapy, guidelines development, drug history talking and medication reconciliation, therapeutic drug monitoring and other blood results monitoring to optimise drug therapies, patient education such as developing of patient leafl ets and delivering of patient education talks, patient counselling of discharged medications such as using of tailored-made discharge medication card, discharge planning to reduce the waiting time, adverse drugs reactions monitoring, medication incidents management, drugs interactions, advice on drug administration (e.g. with or aft er food, timing of drug administration, method of IV drug administration), review of medications in the out-patient clinics aft er discharge, and participation in the clinical trials.